Tuberculin skin test conversion in patientsunder treatment with anti-tumornecrotizing factor alpha agents
Tuberculin skin test conversion in patientsunder treatment with anti-tumornecrotizing factor alpha agents
نویسندگان: علیرضا خبازی اسکویی , محمد اسمعیل حجازی , علی اصغر ابراهیمی چهارم , عاطفه احمدزاده , مریم فرمانی , یاسین حجازی
کلمات کلیدی: Tuberculin skin test, Anti-TNF-alpha agents, Tuberculosis
نشریه: 4980 , 464 , 20 , 2020
| نویسنده ثبت کننده مقاله |
علیرضا خبازی اسکویی |
| مرحله جاری مقاله |
تایید نهایی |
| دانشکده/مرکز مربوطه |
بیماری های بافت همبند |
| کد مقاله |
72769 |
| عنوان فارسی مقاله |
Tuberculin skin test conversion in patientsunder treatment with anti-tumornecrotizing factor alpha agents |
| عنوان لاتین مقاله |
Tuberculin skin test conversion in patientsunder treatment with anti-tumornecrotizing factor alpha agents |
| ناشر |
6 |
| آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ |
خیر |
| عنوان نشریه (خارج از لیست فوق) |
|
| نوع مقاله |
Original Article |
| نحوه ایندکس شدن مقاله |
ایندکس شده سطح یک – ISI - Web of Science |
| آدرس لینک مقاله/ همایش در شبکه اینترنت |
|
| Background: Despite successful clinical outcomes of biologic medications in patients with chronic rheumatic
diseases, some considerable adverse effects such as infections remain a major concern. Possibility of tuberculosis
(TB) reactivation over treatment with anti-tumor necrotizing factor (TNF) alpha agents has necessitated a screening
test before initiation of treatment. However, screening over the course of treatment is not recommended in those
patients with negative baseline screening tests. This study aimed to evaluate the efficacy of tuberculin skin test
(TST) before treatment in patients with chronic rheumatologic diseases who were indicated to receive anti-TNFalpha therapy and the necessity of repeating this test over the course of treatment.
Methods: In this prospective study, patients with chronic rheumatologic diseases receiving anti-TNF-alpha agents
were studied in a two-year period. TST was performed before treatment and those with positive results were
excluded from the study. Thereafter, treatment with anti-TNF-alpha agents was initiated with the indicated dose.
TST was repeated before administration of biologic treatment until TST became positive or 16 weeks after the
initiation of treatment with anti-TNF-alpha.
Results: A total of 51 cases were studied, of whom one patient (1.9%) was excluded due to positive TST before treatment.
All participants received infliximab and the TST test became positive in one patient (2%) 2 weeks after receiving the first
dose. Also, the results of further tests at weeks 6, 10, and 14 were all negative for the remaining patients.
Conclusion: Due to the possibility of TST conversion after administration of anti-TNF-alpha therapy, it is important to
consider TB monitoring in patients under treatment with these agents using available methods such as TST. |
| نام فایل |
تاریخ درج فایل |
اندازه فایل |
دانلود |
| Tuberculin skin test conversion in patients.pdf | 1399/04/13 | 540953 | دانلود |